Selected article for: "clinical improvement and respiratory distress"
Author: La Rosée, F.; Bremer, H. C.; Gehrke, I.; Kehr, A.; Hochhaus, A.; Birndt, S.; Fellhauer, M.; Henkes, M.; Kumle, B.; Russo, S. G.; La Rosée, P.
Title: The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
  • Cord-id: ds6ovq99
  • Document date: 2020_6_9
    • ID: ds6ovq99
    Snippet: A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by t
    Document: A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th(,) 2020, 14 patients with a CIS ≥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by ≥25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure. A multicenter phase-II clinical trial has been initiated (NCT04338958).

    Search related documents:
    Co phrase search for related documents
    • academic teaching and lung disease: 1
    • acetylsalicylic acid and acute ards respiratory distress syndrome: 1
    • acetylsalicylic acid and liver damage: 1
    • acetylsalicylic acid and low molecular: 1, 2, 3, 4, 5
    • acetylsalicylic acid and macrophage activation: 1, 2
    • acetylsalicylic acid and macrophage activation syndrome: 1, 2
    • active infection and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • active infection and liver damage: 1, 2
    • active infection and liver function: 1, 2, 3, 4
    • active infection and low molecular: 1, 2, 3
    • active infection and lung cancer: 1, 2, 3, 4, 5, 6, 7
    • active infection and lung damage: 1, 2, 3, 4, 5, 6
    • active infection and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • active infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and macrophage activation: 1, 2
    • active infection and macrophage activation syndrome: 1
    • active infection patient and acute ards respiratory distress syndrome: 1
    • active infection patient and liver damage: 1
    • active infection patient and liver function: 1